Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.58 USD | -4.51% | -2.95% | -2.86% |
May. 07 | Truist Securities Raises Price Target on OrthoPediatrics to $38 From $35, Maintains Hold Rating | MT |
May. 07 | Transcript : OrthoPediatrics Corp., Q1 2024 Earnings Call, May 07, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.86% | 753M | D+ | ||
+13.73% | 130B | A- | ||
-8.17% | 10.99B | A- | ||
+41.80% | 5.67B | B+ | ||
-21.94% | 4.72B | C | ||
+7.81% | 3.42B | C- | ||
-10.26% | 2.76B | B- | ||
-10.29% | 2.11B | - | - | |
-13.58% | 1.92B | - | ||
-27.77% | 1.68B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KIDS Stock
- Ratings OrthoPediatrics Corp.